PubMed Health⌕ Search

Biomedical subjects

Tao Jing

Publications and source records attributed to Tao Jing.

2 recordsLinked to original sources
PubMed2026

Streptomyces violaceusniger WZS5-6 suppresses Fusarium oxysporum f. sp. cubense tropical race 4 via antifungal metabolites and host defense induction.

INTRODUCTION: Fusarium wilt of banana (FWB), caused by Fusarium oxysporum f. sp. cubense tropical race 4 (Foc TR4), poses a serious threat to the safety and sustainable development of the banana industry. Biological control represents one of the most environmentally friendly approaches for managing this disease. METHODS: In this study, Streptomyces violaceusniger WZS5-6 antifungal activity against Foc TR4 has been investigated through an integrated approach combining antifungal assays, genome analysis, and metabolomic profiling. For the purpose, the effects of the bacterial strain and its cell-free extract on morphological and ultrastructural changes on pathogenic fungal hyphae and spores were assessed using scanning and transmission electron microscopy. LC-MS analysis was used to identify the metabolites responsible for antifungal activity. We further explored the potential of S. violaceusniger WZS5-6 against Foc TR4 through in planta validation. RESULTS: Streptomyces violaceusniger WZS5-6 exhibited a strong inhibition rate of 91.57% on Foc TR4. The cell-free extract obtained from S. violaceusniger WZS5-6 strongly inhibited Foc TR4 with an EC50 value of 91.62 µg·mL-1, indicating the presence of antifungal bioactive metabolites. The results showed that S. violaceusniger WZS5-6 significantly inhibited the mycelial growth of Foc TR4 and induced alterations in spore morphology, mycelial ultrastructure, and cell membrane leakage. Metabolomic profiling of the S. violaceusniger WZS5-6 extracts revealed numerous antifungal metabolites, among which the key metabolites, viz., citronellic acid and furanodienone, exhibited strong inhibitory effects on Foc TR4, with antifungal activity of 61.13% and 57.44%, respectively. Moreover, strain WZS5-6 not only demonstrated 61.54% control efficacy against FWB in a pot experiment but also showed promising growth-promoting effects on banana plants. DISCUSSION: This study demonstrates that S. violaceusniger WZS5-6 inhibits Foc TR4 through a multi-level mechanism involving cellular disruption, metabolic adaptation, and activation of host defense responses. These findings highlight the potential of S. violaceusniger WZS5-6 as a promising novel candidate strain to be employed as a biological control agent of FWB.

Fusarium wilt of banana↗
PubMed2025

Integrating network pharmacology and experimental validation to uncover the synergistic effects of Huangqi ()-Ezhu () with 5-fluorouracil in colorectal cancer models.

OBJECTIVE: To evaluate the effects of Huangqi (Radix Astragali Mongolici)-Ezhu (Rhizoma Curcumae Phaeocaulis) (HQEZ) on colorectal cancer therapies and to elucidate the potential mechanisms of HQEZ, especially in combination with 5-Fluorouracil (5-FU). METHODS: The anti-tumor effects of HQEZ were evaluated in colorectal cancer models both in vivo and in vitro. The network pharmacological assay was used to investigate potential mechanisms of HQEZ. Potential target genes were selected by Gene Ontology (GO) enrichment analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis, protein-protein interaction network (PPI) and molecular docking. Within key targets, potential targets related to drug sensitivity, especially the sensitivity to 5-FU, were evaluated in HCT116 in vitro by immunofluorescence, quantitative real-time polymerase chain reaction (qPCR) and Western-blot. Then, changes in potential targets were assessed in tumors from tumor-bearing mice and the expression of these targets was also evaluated in colorectal cancer (COAD) patients from the Cancer Genome Atlas Program (TCGA) database. RESULTS: HQEZ significantly enhanced the anti-tumor activity of 5-FU in vivo and inhibit the growth of HCT116 in vitro. By network pharmacological analysis, key targets, such as protein kinase B (AKT1), epidermal growth factor receptor (EGFR), adenosine triphosphate (ATP) binding cassette subfamily B member 1 (ABCB1, also named multidrug resistance protein 1, MDR1), ATP binding cassette subfamily G member 2 (ABCG2), thymidylate synthetase (TYMS, also named TS), prostaglandin-endoperoxide synthase 2 (PTGS2), matrix metallopeptidase 2 (MMP2), MMP9, toll like receptor 4 (TLR4), TLR9 and dihydropyrimidine dehydrogenase (DPYD), were identified. Additionally, 4 potential core active ingredients (Folate, Curcumin, quercetin and kaempferol) were identified to be important for the treatment of colorectal cancer with HQEZ. In key targets, chemoresistance related targets were validated to be affected by HQEZ. Furthermore, 5-FU sensitivity related targets, including MDR1, TS, EGFR, ribonucleotide reductase catalytic subunit M1, Breast and Ovarian Cancer Susceptibility Protein 1 (BRCA1) and mutl homolog 1 were also significantly reduced by HQEZ both in vitro and in vivo. Finally, these validated key targets and 5-FU sensitivity related targets were demonstrated to be up-regulated in COAD patients based on TCGA database. CONCLUSION: HQEZ has synergistic effects on the anti-tumor activity of 5-FU in the treatment of colorectal cancer both in vivo and in vitro. The beneficial effect of HQEZ results from the inhibition of the drug sensitivity targets associated with 5-FU. The combination therapy of HQEZ with 5-FU or other chemotherapeutic drugs will also improve the anti-tumor efficacy of chemotherapy.

Humans↗